# Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

Source: https://onco.cc/trials/nct07294261/  
OnCo record `nct07294261` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in lung cancer, run by Sun Yat-sen University, not yet recruiting.

## Summary

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC is a phase 2, randomised interventional study registered as NCT07294261 by Sun Yat-sen University, with a registry enrolment figure of 69 participants, started 2025-12-23 and due to reach its primary completion in 2028-10-30. Interventions recorded: Garsorasib, Benmelstobart, Anlotinib; Benmelstobart, Anlotinib; Garsorasib, Cetuximab Beta Injection. Conditions listed: Local Advanced or Metastatic NSCLC. Primary outcome: Overall response rate (ORR); DoR. Lung eligibility wording from the registry: "Histologically confirmed IIIB-IV NSCLC". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07294261
- Phase: 2
- Setting: A Multicenter, Prospective Clinical Study Evaluating Goselasib Combination Therapy for First-Line Treatment of KRAS G12C Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Sun Yat-sen University
- Enrolled: 69

## Sources

- ClinicalTrials.gov NCT07294261: https://clinicaltrials.gov/study/NCT07294261

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07294261.json